NO20083690L - Hydantoin baserte kinase-inhibitorer - Google Patents
Hydantoin baserte kinase-inhibitorerInfo
- Publication number
- NO20083690L NO20083690L NO20083690A NO20083690A NO20083690L NO 20083690 L NO20083690 L NO 20083690L NO 20083690 A NO20083690 A NO 20083690A NO 20083690 A NO20083690 A NO 20083690A NO 20083690 L NO20083690 L NO 20083690L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- kinase inhibitors
- based kinase
- hydantoin based
- diseases
- Prior art date
Links
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 title 1
- 229940091173 hydantoin Drugs 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77565806P | 2006-02-22 | 2006-02-22 | |
| US86110506P | 2006-11-27 | 2006-11-27 | |
| PCT/EP2007/051313 WO2007096259A1 (en) | 2006-02-22 | 2007-02-12 | Hydantoin based kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083690L true NO20083690L (no) | 2008-09-18 |
Family
ID=37891469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083690A NO20083690L (no) | 2006-02-22 | 2008-08-27 | Hydantoin baserte kinase-inhibitorer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7612212B2 (es) |
| EP (1) | EP1989186B1 (es) |
| JP (1) | JP2009527521A (es) |
| KR (1) | KR101060981B1 (es) |
| AR (1) | AR059590A1 (es) |
| AT (1) | ATE488505T1 (es) |
| AU (1) | AU2007217611B2 (es) |
| BR (1) | BRPI0708182A2 (es) |
| CA (1) | CA2642794A1 (es) |
| CR (1) | CR10208A (es) |
| DE (1) | DE602007010592D1 (es) |
| EC (1) | ECSP088693A (es) |
| IL (1) | IL193482A (es) |
| MA (1) | MA30232B1 (es) |
| NO (1) | NO20083690L (es) |
| RU (1) | RU2008137526A (es) |
| TW (1) | TW200804299A (es) |
| WO (1) | WO2007096259A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| MX2010001581A (es) * | 2007-08-16 | 2010-03-15 | Hoffmann La Roche | Hidantoinas substituidas. |
| FR2920774B1 (fr) * | 2007-09-06 | 2009-10-30 | Galderma Res & Dev | Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant |
| US8063085B2 (en) | 2007-12-20 | 2011-11-22 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| US8530457B2 (en) * | 2008-05-20 | 2013-09-10 | Fox Chase Cancer Center | Method for the treatment of lymphangioleiomyomatosis (LAM) |
| AU2009330686B2 (en) | 2008-06-16 | 2014-07-03 | The Ohio State University Research Foundation | Compounds for the treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| FR2946341B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
| FR2946345B1 (fr) * | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
| FR2946342B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
| FR2946340B1 (fr) * | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
| EP3028699B1 (en) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
| JP6835472B2 (ja) * | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
| BR112016007396B1 (pt) * | 2013-10-25 | 2021-01-19 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| CA3067941C (en) * | 2017-06-23 | 2020-08-18 | Cstone Pharmaceuticals | Coumarin-like cyclic compound as mek inhibitor and use thereof |
| CN114478447B (zh) * | 2020-11-13 | 2024-12-13 | 江苏恒瑞医药股份有限公司 | 苯并含氧环类衍生物、其制备方法及其在医药上的应用 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3434680A1 (de) * | 1984-09-21 | 1986-04-03 | Cassella Ag, 6000 Frankfurt | 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| KR19990012061A (ko) | 1997-07-26 | 1999-02-25 | 성재갑 | 파네실 전이효소 저해제로 유용한 하이덴토인 유도체 |
| AU2001252270B2 (en) | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| ATE404556T1 (de) | 2004-08-17 | 2008-08-15 | Hoffmann La Roche | Substituierte hydantoine |
| TW200621766A (en) | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
-
2007
- 2007-01-25 US US11/657,800 patent/US7612212B2/en not_active Expired - Fee Related
- 2007-02-12 DE DE602007010592T patent/DE602007010592D1/de active Active
- 2007-02-12 RU RU2008137526/04A patent/RU2008137526A/ru not_active Application Discontinuation
- 2007-02-12 AT AT07726336T patent/ATE488505T1/de not_active IP Right Cessation
- 2007-02-12 EP EP07726336A patent/EP1989186B1/en active Active
- 2007-02-12 KR KR1020087020701A patent/KR101060981B1/ko not_active Expired - Fee Related
- 2007-02-12 CA CA002642794A patent/CA2642794A1/en not_active Abandoned
- 2007-02-12 WO PCT/EP2007/051313 patent/WO2007096259A1/en not_active Ceased
- 2007-02-12 JP JP2008555743A patent/JP2009527521A/ja active Pending
- 2007-02-12 BR BRPI0708182-0A patent/BRPI0708182A2/pt not_active IP Right Cessation
- 2007-02-12 AU AU2007217611A patent/AU2007217611B2/en not_active Expired - Fee Related
- 2007-02-16 TW TW096105927A patent/TW200804299A/zh unknown
- 2007-02-20 AR ARP070100715A patent/AR059590A1/es unknown
-
2008
- 2008-08-14 CR CR10208A patent/CR10208A/es not_active Application Discontinuation
- 2008-08-14 IL IL193482A patent/IL193482A/en not_active IP Right Cessation
- 2008-08-21 EC EC2008008693A patent/ECSP088693A/es unknown
- 2008-08-27 NO NO20083690A patent/NO20083690L/no not_active Application Discontinuation
- 2008-08-27 MA MA31198A patent/MA30232B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070197617A1 (en) | 2007-08-23 |
| DE602007010592D1 (de) | 2010-12-30 |
| IL193482A0 (en) | 2009-05-04 |
| AR059590A1 (es) | 2008-04-16 |
| AU2007217611A1 (en) | 2007-08-30 |
| BRPI0708182A2 (pt) | 2011-05-17 |
| TW200804299A (en) | 2008-01-16 |
| JP2009527521A (ja) | 2009-07-30 |
| RU2008137526A (ru) | 2010-03-27 |
| IL193482A (en) | 2012-01-31 |
| US7612212B2 (en) | 2009-11-03 |
| CA2642794A1 (en) | 2007-08-30 |
| ECSP088693A (es) | 2008-09-29 |
| ATE488505T1 (de) | 2010-12-15 |
| CR10208A (es) | 2008-09-22 |
| AU2007217611B2 (en) | 2012-08-23 |
| KR20080091491A (ko) | 2008-10-13 |
| EP1989186B1 (en) | 2010-11-17 |
| WO2007096259A1 (en) | 2007-08-30 |
| EP1989186A1 (en) | 2008-11-12 |
| MA30232B1 (fr) | 2009-02-02 |
| KR101060981B1 (ko) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083690L (no) | Hydantoin baserte kinase-inhibitorer | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| UA102828C2 (en) | Amino triazoles as p13k inhibitors | |
| EA200802050A1 (ru) | Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| EA201500278A1 (ru) | Пиразолилхиназолиновые ингибиторы киназы | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| EA201290305A1 (ru) | Производные трициклического пиразоламина | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
| NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
| GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| NO20076412L (no) | Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav | |
| MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
| MX2009002657A (es) | Derivados dibenzofurano como inhibidores de pde-4 y pde-10. | |
| EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
| PH12012501768A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| IN2014KN00929A (es) | ||
| UA94129C2 (ru) | Соединения для ингибирования митоза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |